ARTICLE | Clinical News
Volanesorsen: Phase III started
December 7, 2015 8:00 AM UTC
Isis began a double-blind, placebo-controlled, international Phase III trial to evaluate 300 mg subcutaneous volanesorsen once weekly for 12 months in about 50 patients. ...